| |MARCH 20249AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in pre-clinical development.OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for resolving chronic inflammation, modulating the functions of both macrophages and neutrophils."This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism of action to treat chronic inflammation.""We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward," said Nicolas Poirier, chief executive officer of OSE Immunotherapeutics. "This partnership represents a major milestone in our company's progress and recognizes the value of our innovative RandD capabilities. I want to thank our employees who helped us achieve this milestone."Under the terms of the agreement, AbbVie has an exclusive worldwide license to develop, manufacture and commercialize OSE-230. OSE Immunoterapia will receive an additional $48 million. Front. For OSE immunotherapy and an additional $665 million for clinical development, regulatory and commercial activities, and available fees. Rodino Antitrust Improvements Act. PORoche Pharma India reported the launch of its blockbuster advancement drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis (MS), growing its nervous system science portfolio to take special care of neglected needs of various patients wrestling with this weakening illness in India. Most people are determined to have different sclerosis between the ages of 20 and 40, making the illness a main source of non-horrendous handicaps in more youthful grown-ups.It is the main monoclonal immune response drug supported for the treatment of both RRMS and PPMS with over ten years of clinical and Certifiable information that features:More than 80 percent of individuals with RRMS and more than 33 percent of individuals with PPMS treated with Ocrevus gave no indications of incapacity movement. Beginning Ocrevus two years sooner saved about ten years of sickness movement in individuals with RRMS. Around 92 percent of individuals with RRMS who got Ocrevus before didn't require a mobile guide, and 80 percent of individuals with PPMS didn't need a wheelchair following ten years of starting and consistent treatment with Ocrevus.Patients on Ocrevus have the most noteworthy perseverance and better adherence than treatment due to its two times yearly (when at regular intervals) dosing, which is ideal for most patients contrasted with more incessant (month to month) infusions.Commenting on the launch, V Simpson Emmanuel, CEO and managing director, Roche Pharma India said, "The introduction of Ocrevus represents a pivotal moment in the management of multiple sclerosis in India. Boasting formidable efficacy, streamlined administration, and a commendable long-term safety record, Ocrevus instils fresh optimism in individuals grappling with this formidable neurological condition. As a blockbuster drug and Roche's flagship globally, launch of Ocrevus in India underscores our commitment to providing innovative solutions to address the burden of neurological disorders that is already one of the biggest health challenges globally and is only set to grow significantly." POABBVIE & OSE COLLABORATE ON OSE-230 MONOCLONAL ANTIBODY FOR CHRONIC INFLAMMATIONROCHE PHARMA INTRODUCES OCREVUS FOR MULTIPLE SCLEROSIS TREATMENT IN INDIATOP STORIES
< Page 8 | Page 10 >